Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(21):1789; doi:10.1093/jnci/91.21.1789
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 21, 1789, November 3, 1999
© 1999 Oxford University Press

IN THIS ISSUE

Risks and Benefits of Tamoxifen Therapy

Tamoxifen treatment has been shown in a randomized placebo-controlled trial to reduce substantially the risk of invasive breast cancer in a population of women at elevated risk. However, tamoxifen treatment is associated with some health-related risks, e.g., endometrial cancer, stroke, pulmonary embolism, and deep vein thrombosis. Gail et al. (p. 1829) have developed tools to assist in counseling women about the use of tamoxifen and in weighing the risks and benefits of treatment with this drug. They find that the risks and benefits of tamoxifen depend on age and race, as well as on a woman's specific . . . [Full Text of this Article]

Counseling Adolescents About Smoking

DNA Alterations in Lung Cancer

Fenretinide and Prevention

PTEN, Integrins, and Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?